↓ Skip to main content

High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?

Overview of attention for article published in Clinical Cancer Research, October 2006
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
wikipedia
5 Wikipedia pages

Citations

dimensions_citation
276 Dimensions

Readers on

mendeley
111 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities?
Published in
Clinical Cancer Research, October 2006
DOI 10.1158/1078-0432.ccr-06-0841
Pubmed ID
Authors

Øyvind S. Bruland, Sten Nilsson, Darrell R. Fisher, Roy H. Larsen

Abstract

The bone-seeking, alpha-particle-emitting radiopharmaceutical Alpharadin, 223RaCl2 (half-life=11.4 days), is under clinical development as a novel treatment for skeletal metastases from breast and prostate cancer. This article summarizes the current status of preclinical and clinical research on 223RaCl2. Potential advantages of 223Ra to that of external beam irradiation and registered beta-emitting bone seekers are discussed. Published data of 223Ra dosimetry in mice and a therapeutic study in a skeletal metastases model in nude rats have indicated significant therapeutic potential of bone-seeking alpha-emitters. This article provides short-term and long-term results from the first clinical single dosage trial. We also present data from a repeated dosage study of five consecutive injections of 50 kBq/kg body weight, once every 3rd week, or two injections of 125 kBq/kg body weight, 6 weeks apart. Furthermore, interim results are described for a randomized phase 2 trial involving 64 patients with hormone-refractory prostate cancer and painful skeletal metastases who received four monthly injections of 223Ra or saline as an adjuvant to external beam radiotherapy. Lastly, we present preliminary dose estimates for 223Ra in humans. Results indicate that repeated dosing is feasible and toxicity is low, and that opportunities are available for combined treatment strategies.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Italy 2 2%
United Kingdom 1 <1%
Unknown 108 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 21 19%
Student > Master 15 14%
Other 13 12%
Student > Bachelor 12 11%
Student > Ph. D. Student 12 11%
Other 22 20%
Unknown 16 14%
Readers by discipline Count As %
Medicine and Dentistry 48 43%
Agricultural and Biological Sciences 8 7%
Biochemistry, Genetics and Molecular Biology 7 6%
Physics and Astronomy 7 6%
Engineering 6 5%
Other 11 10%
Unknown 24 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 June 2022.
All research outputs
#6,496,600
of 21,467,494 outputs
Outputs from Clinical Cancer Research
#5,965
of 12,210 outputs
Outputs of similar age
#37,293
of 118,512 outputs
Outputs of similar age from Clinical Cancer Research
#58
of 125 outputs
Altmetric has tracked 21,467,494 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 12,210 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 118,512 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 125 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.